Day One Biopharmaceuticals (DAWN) Share-based Compensation (2022 - 2025)
Historic Share-based Compensation for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $9.6 million.
- Day One Biopharmaceuticals' Share-based Compensation fell 1724.94% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year decrease of 766.88%. This contributed to the annual value of $48.3 million for FY2024, which is 2267.86% up from last year.
- Per Day One Biopharmaceuticals' latest filing, its Share-based Compensation stood at $9.6 million for Q3 2025, which was down 1724.94% from $10.9 million recorded in Q2 2025.
- Over the past 5 years, Day One Biopharmaceuticals' Share-based Compensation peaked at $13.0 million during Q2 2024, and registered a low of $5.6 million during Q2 2022.
- Moreover, its 4-year median value for Share-based Compensation was $9.6 million (2023), whereas its average is $9.9 million.
- As far as peak fluctuations go, Day One Biopharmaceuticals' Share-based Compensation soared by 6830.05% in 2023, and later crashed by 1724.94% in 2025.
- Day One Biopharmaceuticals' Share-based Compensation (Quarter) stood at $6.8 million in 2022, then surged by 58.22% to $10.8 million in 2023, then grew by 2.07% to $11.0 million in 2024, then decreased by 13.36% to $9.6 million in 2025.
- Its Share-based Compensation was $9.6 million in Q3 2025, compared to $10.9 million in Q2 2025 and $12.9 million in Q1 2025.